In analyses adjusted for potential confounders, subjects with the AC or AC + CC genotype of the FSCN1 rs56156320 polymorphism were almost twice as likely as those with AA homozygotes to develop breast cancer (adjusted odds ratio [AOR], 2.060; 95% CI: 1.020–4.157 or AOR, 1.736; 95% CI: 1.105–2.727; p < 0.05). Here, FSCN1 is linked to breast cancer.